- Home
- GERN vs TRIP Comparison
GERN vs TRIP Comparison
Compare GERN & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | TRIP |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GERN | TRIP |
|---|---|---|
| Price | $1.46 | $9.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 13 |
| Target Price | $2.17 | ★ $14.88 |
| AVG Volume (30 Days) | ★ 16.5M | 3.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 675.00 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $1,556,000,000.00 |
| Revenue This Year | $32.27 | $4.02 |
| Revenue Next Year | $60.16 | $5.19 |
| P/E Ratio | ★ N/A | $32.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $9.46 |
| 52 Week High | $2.01 | $20.16 |
Technical Indicators
Market Signals| Indicator | GERN | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 30.42 |
| Support Level | $1.20 | $9.46 |
| Resistance Level | $1.68 | $15.51 |
| Average True Range (ATR) | 0.16 | 0.68 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 5.08 | 13.31 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform (33% of 2024 sales). Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).